2018 American Transplant Congress
Micafungin Prophylaxis in Liver Transplant Recipients at High Risk for Invasive Fungal Infections
Medstar Georgetown University Hospital, Department of Pharmacy, Washington, DC.
Purpose: This study was conducted to determine the incidence of proven or probable invasive fungal infections in the first 90 days after transplant in high…2018 American Transplant Congress
Increase in Potentially Resistant Non-Aspergillus Molds Isolated in Lung Transplant Recipients after Voriconazole and Posaconazole Prophylaxis
Background: Lung transplant recipients are at higher risk for invasive fungal infections compared to other solid organs transplant patients. Antifungal prophylaxis with mold-active azoles has…2018 American Transplant Congress
Infection Outcomes in Solid Organ Transplant Recipients Receiving Trimethoprim-Sulfamethoxazole as Opposed to Atovaquone for Prophylaxis
Background: Pneumocystis jiroveci pneumonia (PJP) is an important illness amongst solid organ transplant (SOT) recipients. Trimethoprim-sulfamethoxazole (TMP-SMX) is the prophylaxis of choice based on efficacy…2018 American Transplant Congress
Making Sense of Hepatitis B Reactivation Risk in Anti-HBc Antibody (Ab) Positive Liver Transplant Recipients
Background: Limited data exists regarding the rates of reactivation of hepatitis B virus (HBV) in anti-HBc Ab positive orthotopic liver transplant (OLT) recipients. Protocols vary…2018 American Transplant Congress
Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients
1University of British Columbia, Vancouver, Canada; 2University of Manitoba, Winnipeg, Canada.
Introduction: Donor-derived primary Epstein-Barr virus (EBV) infection poses serious risks to EBV naïve children post-solid organ transplantation, including development of EBV-related PTLD. Currently, there is…2018 American Transplant Congress
A Retrospective Review of De Novo Coccidioidomycosis among Remote Solid Organ Transplant Recipients in Arizona
Background: Solid organ transplant (SOT) recipients residing in a Coccidioides-endemic region that acquire infection are at risk for complicated and protracted infection. Following transplantation, prophylaxis…2018 American Transplant Congress
Pneumocystis jiroveci Pneumonia (PJP) in Kidney and Pancreas Transplant Recipients in the Present Era of Routine Post-Transplant Prophylaxis: Risk Factors and Outcomes
University of Wisconsin, Madison.
PJP after transplant (TX) is associated with substantial morbidity and mortality. In the present era of universal and routine implementation of PJP prophylaxis (PPX) during…2018 American Transplant Congress
Impact of Pneumocystis Prophylaxis on Incidence of Treated Urinary Tract Infections Following Kidney Transplantation
Rush University Medical Center, Chicago, IL.
Background: Urinary tract infection (UTI) is the most common infectious complication after kidney transplantation resulting in increased morbidity and mortality. Sulfamethoxazole[mdash]trimethoprim (SMX-TMP) is commonly used…2018 American Transplant Congress
Standard- versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients
Henry Ford Hospital, Detroit, MI.
Background: Although guidelines recommend valganciclovir (VGC) 900 mg daily for cytomegalovirus (CMV) prophylaxis in solid organ transplant patients, multiple centers have reported clinical success, reduced…2018 American Transplant Congress
Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients
A. Prophylaxis has mostly replaced preemptive therapy in CMV seronegative recipients of kidneys from seropositive donors (D+/R-). Primary infections occur commonly even after six months…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 14
- Next Page »